Recently, the National Healthcare Security Administration (NHSA) adjusted and released the “Standards of the Contract Renewal of Reimbursed Drugs,” which clarified the adjusted payment standards covering the entire life-cycle of drugs: A drug that has been on the reimbursement list for 8 years will stay on the list permanently; the price reduction of a reimbursed drug would be halved if this drug has been on the reimbursement list for more than 4 years and the price reduction is triggered by contract renewal or additional indications for this drug; innovative drugs, biological goods, and traditional Chinese medicines that have already been approved by the Measures for the Administration of Drug Registration can renew the contract through renegotiations with the state if the price reduction is triggered.
基本覆盖药品全生命周期 国家医保局发布谈判药品续约规则
来源：广东省人民政府 2023.07.24
国家医保局日前对《谈判药品规则续约》进行调整完善并发布，明确建立基本覆盖药品全生命周期的支付标准调整规则：对达到8年的谈判药纳入常规目录管理；对未达8年的谈判药，连续协议期达到或超过4年的品种以简易方式续约或新增适应症触发降价的，降幅减半；对于按照现行注册管理办法批准的1类化药、1类治疗用生物制剂，1类和3类中成药，在续约触发降价机制时，可以申请以重新谈判的方式续约。
Leave a Reply